Curis reports Q3 EPS ($2.13), consensus ($2.33)

Reports Q3 revenue $2.8M, consensus $2.54M. “Since the removal of the partial clinical hold, we have re-started patient enrollment in both the Phase 1/2 TakeAim Leukemia monotherapy and TakeAim Lymphoma combination studies and expect to initiate a triplet combination study in AML in the fourth quarter. We also expect to present updated data from the TakeAim Lymphoma combination study at ASH in December,” said James Dentzer, President and CEO of Curis. Curis’s cash, cash equivalents and investments totaled $68.5M, and the company had approximately 5.9M shares of common stock outstanding. Curis expects its existing cash, cash equivalents and investments to enable its planned operations into 2025.